Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
|Videos|November 3, 2021
Integrative Medicine Can Be Combined With Oncology Treatment for Neuroendocrine Tumors
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center, discusses how integrative medicine can help treatment of neuroendocrine tumors in combination with other treatments.
Advertisement
In a Pharmacy Times® interview, Kaushal Nanavati, MD, FAAFP, ABOIM, ABIHM assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center, spoke about his 2021 NANETS presentation on the integrative management of neuroendocrine tumors (NETs).
He discussed how integrative medicine can help treatment of NETs in combination with other treatments.
Advertisement
Related to this article
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
5